Reprise Biomedical
Plymouth
About Reprise Biomedical
Reprise Biomedical is a Minnesota-based startup focused on commercializing biological medical devices manufactured using a proprietary perfusion decellularization technology that supports cellular integration. Reprise was created in connection with a spin-off from Miromatrix Medical Inc. in June 2019. Through the spin-off, Miromatrix transferred to Reprise two existing FDA 510(k) cleared, commercially available medical devices – MIROMESH Biologic Matrix and MIRODERM® Biologic Wound Matrix – as well as all acellular medical devices in development. MIROMESH and MIRODERM are derived via perfusion decellularization of the highly vascularized porcine liver. A non-crosslinked surgical mesh, MIROMESH comes in a variety of sizes suited for hernia repair applications. MIRODERM is indicated for the management of wounds, including diabetic foot ulcers, venous ulcers, pressure ulcers, and surgical and trauma wounds.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $47.1M
- Last round: Series Unknown (Jul 2025)
- Website: reprisebio.com
- Phone: 763-284-6780
Industries & Categories
Biotechnology, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/reprise-biomedical-23726 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.